SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b/2 Trial Evaluating Nirogacestat in Combination with Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma

NEXT STORY
Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
PREV STORY
Global Ambulance Services Market (2021 to 2026) – Industry Trends, Share, Size, Growth, Opportunity and Forecasts
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients

- Safety Profile of Combination Therapies Consistent with Single Agent IDHm Inhibitors and Azacitidine ...

author_avatar
NASDAQ Market News

Interpace Diagnostics Group Reports First Quarter 2018 Financial Results, Business Progress and Recent Accomplishments

Revenue Grew 39% Over the Prior Year’s Quarter and 10% Over the Prior Period ...

author_avatar
NASDAQ Market News

Press release: Terveystalo continues to grow its footprint in well-being services: Kuntoutumisasema OTE Oy to become part of Terveystalo

On 14 December, Terveystalo signed a contract on acquiring the operations of Kuntoutumisasema OTE ...

author_avatar
NASDAQ Market News